Full Press Release Details
Electromed, Inc. Announces Fiscal 2023
Second Quarter Results
Growth initiatives help drive record
NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. ("Electromed")
(NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months
ended December 31, 2022 ("Q2 FY 2023").
Q2 FY 2023 Highlights
"I am very pleased to report record quarterly revenues
for the second fiscal quarter of 2023 and 15% revenue growth from the prior year period as the Electromed team continues to perform
at a high level while executing our multi-pronged strategic growth initiatives. Our performance resulted in improvement in operating
margin and cashflow this quarter which is equally as impressive as the topline growth given the inflationary macroeconomic environment.,"
said Kathleen Skarvan, President and Chief Executive Officer.
"One of our key growth initiatives is the introduction
of our fifth generation SmartVest Clearway, which is now on the market in a limited release. Patient feedback has been overwhelmingly
positive, and we are excited to introduce Clearway to more patients and physicians over the next few months. We continued to expand
the commercial team, which is operating at a high level of productivity, and we believe the building blocks are in place as our
company works to drive our SmartVest Airway Clearance therapy to wider adoption in the airway clearance market."
Fiscal Second Quarter Results
Net revenue for Q2 FY 2023 increased by 14.5% year over year
to $11,729,000, compared to $10,248,000 in the same period in the prior year. The increase over the prior year period was driven
by increased referrals and approvals as a result of an expanded sales force and reimbursement team. Field sales employees totaled
57 as of December 31, 2022, 48 of which were direct sales representatives, compared to 48 field sales employees and 39 direct sales
representatives as of December 31, 2021. Sales force productivity remained within our expected range during the quarter, with annualized
home care revenue per direct sales representative at $927,000, within Electromed's target range of $850,000 to $950,000.
Home care revenue increased by $1,328,000, or 14.1%, for Q2
FY 2023 compared to the same period in the prior year. Institutional revenue increased by $256,000, or 76.9%, for Q2 FY 2023 compared
to the same period in the prior year. Home care distributor revenue decreased by $51,000, or 13.2%, for Q2 FY 2023 compared to
the same period in the prior year. International revenue decreased by $52,000, or 41.9%, for Q2 FY 2023 compared to the same period
Gross profit increased to $8,682,000, or 74.0% of net revenues
for Q2 FY 2023, from $7,880,000, or 76.9% of net revenues, in the same period in the prior year. The decrease in gross profit as
a percentage of net revenues compared to the same period in the prior year is primarily due to increased material costs and higher
shipping expenses to expedite inventory purchases.
Selling, general and administrative ("SG&A")
expenses were $7,254,000 for Q2 FY 2023, representing an increase of $779,000, or 12.0% compared to the same period in the prior
year. The increase was primarily due to additional headcount in our sales and reimbursement departments representing our investments
Operating income for Q2 FY 2023 was $1,274,000, compared to
$1,076,000 for the same period in the prior year. The increase in operating income in the three months ended December 31, 2022
was primarily due to revenue growth partially offset by increased operating expenses reflecting expansion of headcount and other
Net income for Q2 FY 2023 was $977,000, compared to $838,000
for the same period in the prior year. The increase in net income in the three months ended December 31, 2022 was primarily due
As of December 31, 2022, Electromed had $6.9 million in cash,
$21.6 million in accounts receivable, working capital of $28.2 million, and total shareholders' equity of $35.4 million.
Conference Call and Webcast Information
parties may participate in the call by dialing (877) 407-0789 (Domestic) or (201) 689-8562 (International). Listeners may also
bypass the operator and get instant telephone access by using the call me feature via this link:
live webcast of the call will be accessible in the Investor Relations section of Electromed's web site and directly via
the following link: https://viavid.webcasts.com/starthere.jsp?ei=1596017&tp_key=9bc6fba7a8
those who cannot listen to the live broadcast, a replay will be available by dialing (844) 512-2921 (Domestic) or (412) 317-6671
(International) and referencing the replay pin number 13736069. Additionally, an online replay will be available in the Investor
Relations section of Electromed's web site at: http://investors.smartvest.com/.
About Electromed, Inc.
Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance
System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992.
Further information about Electromed can be found at www.smartvest.com.
Cautionary Statements
Certain statements in this press release constitute forward-looking
statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be
identified by words such as "anticipate," "assume," "believe," "continue," "expect,"
"may," "potential," "should," "will," and similar expressions, including the negative
of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed,
and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples
of risks and uncertainties for Electromed include, but are not limited to, component or raw material shortages, changes to lead
times or significant price increases, changes to Medicare, Medicaid, or private insurance reimbursement policies; the duration,
extent and severity of the COVID-19 pandemic, including its effects on our business, supply chain, operations and employees as
well as its impact on our customers and distribution channels and on economies and markets more generally; the competitive nature
of our market; changes to state and federal health care laws; changes affecting the medical device industry; our ability to develop
new sales channels for our products such as the homecare distributor channel; our need to maintain regulatory compliance and to
gain future regulatory approvals and clearances; new drug or pharmaceutical discoveries; general economic and business conditions;
our ability to renew our line of credit or obtain additional credit as necessary; our ability to protect and expand our intellectual
property portfolio; the risks associated with expansion into international markets, as well as other factors we may describe from
time to time in Electromed's reports filed with the Securities and Exchange Commission (including Electromed's most
recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties
or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other
readers should not place undue reliance on "forward-looking statements," as such statements speak only as of the date
of this press release. We undertake no obligation to update them in light of new information or future events.
Brad Nagel, Chief Financial Officer
Mike Cavanaugh, Investor Relations
Financial Tables Follow:
Condensed Balance Sheets
| December 31, 2022 | June 30, 2022 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 6,909,000 | $ | 8,153,000 | ||||
| Accounts receivable (net of allowances for doubtful accounts of $45,000) | 21,555,000 | 21,052,000 | ||||||
| Contract assets | 507,000 | 286,000 | ||||||
| Inventories | 3,473,000 | 3,178,000 | ||||||
| Prepaid expenses and other current assets | 1,720,000 | 1,870,000 | ||||||
| Total current assets | 34,164,000 | 34,539,000 | ||||||
| Property and equipment, net | 5,038,000 | 4,568,000 | ||||||
| Finite-life intangible assets, net | 584,000 | 599,000 | ||||||
| Other assets | 80,000 | 120,000 | ||||||
| Deferred income taxes | 1,528,000 | 1,538,000 | ||||||
| Total assets | $ | 41,394,000 | $ | 41,364,000 | ||||
| Liabilities and Shareholders' Equity | ||||||||
| Current Liabilities | ||||||||
| Accounts payable | 785,000 | 1,261,000 | ||||||
| Accrued compensation | 2,210,000 | 2,742,000 | ||||||
| Income tax payable | 130,000 | 51,000 | ||||||
| Warranty reserve | 1,337,000 | 1,256,000 | ||||||
| Other accrued liabilities | 1,549,000 | 1,840,000 | ||||||
| Total current liabilities | 6,011,000 | 7,150,000 | ||||||
| Other long-term liabilities | 33,000 | 41,000 | ||||||
| Total liabilities | 6,044,000 | 7,191,000 | ||||||
| Commitments and Contingencies | ||||||||
| Shareholders' Equity | ||||||||
| Common stock, $0.01 par value per share, 13,000,000 shares authorized; | ||||||||
| 8,514,164 and 8,475,438 shares issued and outstanding, as of December 31, 2022 and June 30, 2022, respectively | 85,000 | 85,000 | ||||||
| Additional paid-in capital | 18,580,000 | 18,308,000 | ||||||
| Retained earnings | 16,685,000 | 15,780,000 | ||||||
| Total shareholders' equity | 35,350,000 | 34,173,000 | ||||||
| Total liabilities and shareholders' equity | $ | 41,394,000 | $ | 41,364,000 |
Condensed Statements of Operations
| Three Months Ended | Six Months Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Net revenues | $ | 11,729,000 | $ | 10,248,000 | $ | 22,387,000 | $ | 20,249,000 | ||||||||
| Cost of revenues | 3,047,000 | 2,368,000 | 5,374,000 | 4,668,000 | ||||||||||||
| Gross profit | 8,682,000 | 7,880,000 | 17,013,000 | 15,581,000 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Selling, general and administrative | 7,254,000 | 6,475,000 | 15,243,000 | 13,262,000 | ||||||||||||
| Research and development | 154,000 | 329,000 | 452,000 | 705,000 | ||||||||||||
| Total operating expenses | 7,408,000 | 6,804,000 | 15,695,000 | 13,967,000 | ||||||||||||
| Operating income | 1,274,000 | 1,076,000 | 1,318,000 | 1,614,000 | ||||||||||||
| Interest income, net | 7,000 | 6,000 | 11,000 | 15,000 | ||||||||||||
| Net income before income taxes | 1,281,000 | 1,082,000 | 1,329,000 | 1,629,000 | ||||||||||||
| Income tax expense | 304,000 | 244,000 | 271,000 | 352,000 | ||||||||||||
| Net income | $ | 977,000 | $ | 838,000 | $ | 1,058,000 | $ | 1,277,000 | ||||||||
| Income per share: | ||||||||||||||||
| Basic | $ | 0.12 | $ | 0.10 | $ | 0.13 | $ | 0.15 | ||||||||
| Diluted | $ | 0.11 | $ | 0.10 | $ | 0.12 | $ | 0.15 | ||||||||
| Weighted-average common shares outstanding: | ||||||||||||||||
| Basic | 8,442,939 | 8,478,394 | 8,442,684 | 8,501,041 | ||||||||||||
| Diluted | 8,684,352 | 8,760,946 | 8,685,184 | 8,788,194 |
Condensed Statements of Cash Flows
| Six Months Ended December 31, | ||||||||
| 2022 | 2021 | |||||||
| Cash Flows From Operating Activities | ||||||||
| Net income | $ | 1,058,000 | $ | 1,277,000 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation | 272,000 | 221,000 | ||||||
| Amortization of finite-life intangible assets | 47,000 | 79,000 | ||||||
| Share-based compensation expense | 316,000 | 526,000 | ||||||
| Deferred income taxes | 10,000 | 37,000 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (503,000 | ) | (2,082,000 | ) | ||||
| Contract assets | (221,000 | ) | 111,000 | |||||
| Inventories | (321,000 | ) | 334,000 | |||||
| Prepaid expenses and other current assets | 176,000 | (265,000 | ) | |||||
| Income tax payable, net | 79,000 | (366,000 | ) | |||||
| Accounts payable and accrued liabilities | (711,000 | ) | 435,000 | |||||
| Accrued compensation | (532,000 | ) | (413,000 | ) | ||||
| Net cash provided by operating activities | (330,000 | ) | (106,000 | ) | ||||
| Cash Flows From Investing Activities | ||||||||
| Investment in property and equipment | (687,000 | ) | (511,000 | ) | ||||
| Investment in finite-life intangible assets | (30,000 | ) | (69,000 | ) | ||||
| Net cash used in investing activities | (717,000 | ) | (580,000 | ) | ||||
| Cash Flows From Financing Activities | ||||||||
| Issuance of common stock upon exercise of options | 16,000 | - | ||||||
| Taxes paid on stock options exercised on a net basis | (60,000 | ) | (70,000 | ) | ||||
| Repurchase of common stock | (153,000 | ) | (663,000 | ) | ||||
| Net cash used in financing activities | (197,000 | ) | (733,000 | ) | ||||
| Net (decrease) increase in cash | (1,244,000 | ) | (1,419,000 | ) | ||||
| Cash And Cash Equivalents | ||||||||
| Beginning of period | 8,153,000 | 11,889,000 | ||||||
| End of period | $ | 6,909,000 | $ | 10,470,000 |